Christina Lopes is CEO and Founder of the One Health Company, an AI and genomics oncology company. One Health’s novel platform, FidoCure, was validated by Nature (precision oncology) for improving canine cancer outcomes while also demonstrating that studying cancer in dogs can help advance human cancer R&D. One Health’s unique mission to fight cancer on both sides of the leash is backed by both Andreessen Horowitz (a16z bio + health portfolio) and Y-Combinator. Previously, Christina was Managing Director of Cerberus Capital, a private equity firm with $50B under management. She also served as Advisory Board Director for International Planned Parenthood, which serves 30 million
health services per year. The World Economic Forum at Davos recognized Lopes as a Young Global Leader and Inc. Magazine named her a Top100 Female Founder. She is listed as
author of several scientific publications. Christina completed doctoral coursework at Princeton University under Dr. Cornel West and received a Masters from Columbia’s SIPA.

Christina K. Lopes is CEO and Co-founder of One Health Company, and its flagship product Fidocure, the first precision cancer treatment platform for dogs which aims to crush cancer on both sides of the leash. Before founding One Health, Christina was Managing Director of Cerberus Capital, a U.S. private equity firm with $30 billion under management. She previously served as Advisory Board Director for International Planned Parenthood, which provides 30 million health services per year. In this role, she supported the effort to offer pre-cancerous vaccines in Bolivia, democratizing access to underserved people suffering from lack of access to modern cervical cancer care. Her passion for health care accessibility led to her advisory role in The United Nations Commission for the Status of Women, focusing on healthcare. Her expertise in managing multilateral partnerships to innovate healthcare allowed her to found One Health, leading the company and its flagship product FidoCure through the prestigious YCombinator accelerator program and secure A16z as a capital partner.

Christina was selected as Inc. Magazine’s Top100 Female Founders 2019, and was also honored as a Rising Talent by the Women’s Forum in 2014. She has been recognized as a
Young Global Leader by the World Economic Forum at Davos for her pioneering efforts in women’s health and business. She serves as a Trustee for The Common Project, an
inclusive global network connecting consumers to their digital health data to make informed decisions during COVID-19 and beyond. She is listed as author of several scientific publications, including “Analyses of canine cancer mutations and treatment outcomes using real-world clinico-genomics data of 2119 dogs “ which is published in npj (Nature Christina Lopes Bio Partner Journal) Precision Oncology.

She holds a bachelor’s degree from the University of Massachusetts, a master’s degree in International and Political Affairs from Columbia University, and has completed doctoral coursework at Princeton University. Originally from Brazil, Christina is one of the few LatinX CEOs in life science.